GlaxoSmithKline's Benlysta Positive In Continuation Trial
Zacks Investment Research | Jun 18, 2017 10:21PM ET
GlaxoSmithKline plc (NYSE:GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug Benlysta (belimumab) in combination with standard of care for treatment of patients with systemic lupus erythematosus (SLE). The study was presented at the Annual European Congress of Rheumatology (EULAR).
The above is the longest study spanning 10 years, measuring the efficacy and safety of the SLE therapy.
Benlysta is presently approved in the U.S. for treatment of adult patients with an active SLE, who are receiving standard therapy. Additionally, Benlysta is licensed in the EU as an add-on therapy in adults with the given indication. Currently, it is also the only medicine approved for SLE.
Shares of GlaxoSmithKline have outperformed the Zacks classified Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.